NCT04785287View on ClinicalTrials.gov

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

May 27, 2027

Study Completion Date

May 27, 2027

Conditions
Advanced Lung CarcinomaAdvanced Malignant Solid NeoplasmMalignant Adrenal Gland NeoplasmMetastatic Liver CarcinomaMetastatic Lung CarcinomaMetastatic Malignant Solid NeoplasmStage III Liver CancerStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Liver CancerStage IV Lung Cancer AJCC v8Stage IVA Liver CancerStage IVA Lung Cancer AJCC v8Stage IVB Liver CancerStage IVB Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Anti-CTLA4 Monoclonal Antibody BMS-986218

Given IV

BIOLOGICAL

Nivolumab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER